These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11399996)

  • 21. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
    Maxeiner HG; Keulen W; Schuurman R; Bijen M; de Graaf L; van Wijk A; Back N; Kline MW; Boucher CA; Nijhuis M
    J Infect Dis; 2002 Apr; 185(8):1070-6. PubMed ID: 11930317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
    Batisse D; Karmochkine M; Si Mohamed A; Piketty C; Kazatchkine MD; Belec L
    AIDS; 1998 May; 12(7):824-5. PubMed ID: 9619820
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutations in the reverse transcriptase gene of HIV type 1 from subjects after stavudine-didanosine dual therapy.
    Monno L; Appice A; Scarabaggio T; Di Stefano M; Pastore G; Angarano G
    AIDS Res Hum Retroviruses; 2000 May; 16(8):821-3. PubMed ID: 10826489
    [No Abstract]   [Full Text] [Related]  

  • 24. Transmission of zidovudine resistant strains of HIV-1: the first wave.
    Blower S
    AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
    [No Abstract]   [Full Text] [Related]  

  • 25. The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.
    Gianotti N; Galli L; Boeri E; De Bona A; Guffanti M; Danise A; Salpietro S; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):447-52. PubMed ID: 16652052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
    Pellegrin I; Izopet J; Reynes J; Denayrolles M; Montes B; Pellegrin JL; Massip P; Puel J; Fleury H; Segondy M
    AIDS; 1999 Sep; 13(13):1705-9. PubMed ID: 10509572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
    Linde R; Funk MB; Schuster T; Wintergerst U; Notheis G; Klingebiel T; Kreuz W
    AIDS; 2001 May; 15(8):1077-9. PubMed ID: 11399999
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
    Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper DA; Yerly S
    AIDS; 2000 May; 14(8):1065-7. PubMed ID: 10853993
    [No Abstract]   [Full Text] [Related]  

  • 35. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
    Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
    J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.
    Becker SL; Raffanti SR; Hansen NI; Fusco JS; Fusco GP; Slatko GH; Igboko EF; Graham NM;
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):72-81. PubMed ID: 11176271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials.
    Wainberg MA
    Leukemia; 1997 Apr; 11 Suppl 3():85-8. PubMed ID: 9209307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.